Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2026-02-03 Regulatory Filings
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
Regulatory Filings Classification · 95% confidence The document is a press release issued by Addex Therapeutics announcing the publication of scientific research data in the journal 'Molecular Psychiatry'. It follows the standard format of a corporate press release, including an 'Ad Hoc Announcement' header, company boilerplate, and contact information. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement (as it is the primary announcement of the research itself), it falls under the general regulatory/corporate announcement category.
2026-02-03 English
FORM 6-K
Regulatory Filings
2026-01-07 English
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Regulatory Filings Classification · 95% confidence The document is an 'Ad Hoc Announcement' issued by Addex Therapeutics regarding the initiation of a Phase 1 clinical study by its spin-out company, Neurosterix. It provides details on the drug candidate (NTX-253), the clinical trial design, and the company's strategic position. As this is a general corporate announcement regarding business operations and clinical milestones that does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS).
2026-01-07 English
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Capital/Financing Update Classification · 95% confidence The document is an 'Ad Hoc Announcement' regarding an amendment to an 'At The Market' (ATM) offering agreement. It details the company's ability to sell securities through a sales agent, which constitutes a financing activity and a change in capital structure/funding strategy. This fits the definition of a Capital/Financing Update (CAP).
2025-12-11 English
FORM 6-K
Regulatory Filings
2025-12-10 English
424B5
Regulatory Filings
2025-12-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.